Recently, pomiferin has been demonstrated to inhibit HDAC enzyme activity at low micromolar concentrations (IC50 approx. 1 μM) and to inhibit growth of different human cancer cell lines, e.g. kidney, lung, prostate, breast or colon cancer, without affecting the growth of primary human hepatocytes (47). This evidence concerns the gene HDAC9 and colonic neoplasm.